A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medications in Children With ADHD

Last updated: May 25, 2022
Sponsor: Massachusetts General Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Attention Deficit/hyperactivity Disorder (Adhd - Adults)

Williams Syndrome

Treatment

N/A

Clinical Study ID

NCT04189562
2016-P-002715
  • Ages 6-12
  • All Genders

Study Summary

This study will assess the efficacy of the text messaging (SMS-based) disease management intervention for children with Attention Deficit/Hyperactivity Disorder (ADHD) using the timeliness of stimulant prescription renewals over a 9-month period.

Parents of participants in the study will receive customized text messages once a day, Sunday through Friday, for a duration of 9 months. The text messages will include reminders to adhere to the individualized medication regimen, reminders to call their child's clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Children 6-12 years of age of both sexes and their parent
  • A diagnosis of ICD-10 or DSM 5 diagnosis of Attention Deficit/Hyperactivity Disorderincluding the following ICD codes (F90 Attention-deficit hyperactivity disorders;F90.0 Attention-deficit hyperactivity disorder, predominantly inattentive type; F90.1Attention- deficit hyperactivity disorder, predominantly hyperactive type; F90.2Attention-deficit hyperactivity disorder, combined type;F90.8 Attention-deficithyperactivity disorder, other type; F90.9 Attention-deficit hyperactivity disorder,unspecified type) and/or the following DSM 5 diagnoses (314.01, F90.2Attention-deficit/hyperactivity disorder, combined presentation; 314.01, F90.1Attention-deficit/hyperactivity disorder, predominantly hyperactive/impulsivepresentation;314.00, F90.0 Attention- deficit/hyperactivity disorder, predominantlyinattentive presentation)
  • Starting or currently on stimulant medication including (Amphetamine/Dextroamphetamine (Adderall);Dextroamphetamine (Dexedrine, ProCentra, Zenzedi, Adderall XR);Dexmethylphenidate (Focalin, Focalin XR); Methylphenidate (Ritalin, Ritalin SR,Metadate ER, Methylin ER, Concerta, Daytrana, Metadate CD, Quillivant XR, Ritalin LA);Amphetamine sulfate (Evekeo); Lisdexamfetamine (Vyvanse))
  • Proficient in English
  • Has a cellular phone with text messaging capabilities and is interested in and willingto receive free of charge text messages

Exclusion

Exclusion Criteria:

  • Investigator and his/her immediate family
  • Unwilling/unable to comply with study procedures

Study Design

Total Participants: 300
Study Start date:
February 22, 2017
Estimated Completion Date:
June 30, 2023

Connect with a study center

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.